1686149-74-5

Basic information

• Product Name: BMS-589154)
• Synonyms: Apixaban iMpurity(BMS-591455;BMS-589154);BMS-589154)）;BMS-591329;BMS-719288;BMS-724914;BMS-728626;BMS-778960
• CAS NO: 1686149-74-5
• Molecular Formula: C26H27N5O4
• Molecular Weight: 473.52368
• EINECS: -0
• Mol File: 1686149-74-5.mol
• Article Data: 0

Chemical Properties

• Boiling Point: 766.0±60.0 °C(Predicted)
• Appearance: /
• Density: 1.39±0.1 g/cm3(Predicted)
• PKA: 15.01±0.20(Predicted)
• CAS DataBase Reference: BMS-589154)(CAS DataBase Reference)
• NIST Chemistry Reference: BMS-589154)(1686149-74-5)
• EPA Substance Registry System: BMS-589154)(1686149-74-5)

Safety Data

• Hazardous Substances Data: 1686149-74-5(Hazardous Substances Data)

Usage

Description

BMS-589154 is an analytical standard impurity of Apixaban (A726700(P)), a potent, direct, selective, and orally active inhibitor of coagulation factor Xa. It is a potential new oral coagulant with significant applications in the medical field.

Uses

Used in Pharmaceutical Industry:
BMS-589154 is used as an analytical standard impurity for Apixaban, which is a potential new oral coagulant. It plays a crucial role in the development and quality control of Apixaban, ensuring the safety and efficacy of the drug.
Used in Orthopedic Surgery:
BMS-589154, as a part of Apixaban, is used for the prevention of venous thromboembolism in total hip and knee replacement orthopedic surgeries. It helps in reducing the risk of blood clot formation and related complications during and after the surgery.
Used in Stroke Treatment:
BMS-589154, as a component of Apixaban, is utilized in the treatment of patients with venous thromboembolic disorder or atrial fibrillation, which are common risk factors for stroke. It aids in preventing blood clots and reducing the chances of stroke occurrence.
Used in Venous Thromboembolic Disorder Treatment:
BMS-589154, as an impurity in Apixaban, is employed in the treatment of patients with venous thromboembolic disorder. It helps in managing the condition by inhibiting coagulation factor Xa and reducing the risk of blood clot formation.